HALB Halberd Corp.

Halberd Update on WatchDawg® PTSD Treatment

Halberd Update on WatchDawg® PTSD Treatment

Next Phase Pilot Study

JACKSON CENTER, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found . Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studies. The next phase to be conducted on the patent-pending medicines/procedures is a 100-person study which will be conducted in sub-groups as volunteers are identified and qualified. The initial sub-group of 10 volunteers of this 100-person study have been selected. Results from this sub-group should be available around mid-January.



We are awaiting government and pending private investment funding to accelerate the 100-person study currently underway.

To get the latest on Halberd’s exciting developments, subscribe by submitting this .

().

For more information, please contact:

William A. Hartman







Twitter:

About Halberd Corporation.

Halberd Corporation (OTC PINK: ), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners. Halberd’s policy for responding to individual shareholder questions is to be responsive, while refraining from providing information which relates to or could compromise any information pertaining to trade secrets or that may otherwise compromise our competitive advantages. Simultaneously with such disclosure or potential disclosure, Halberd will make the responsive information public through a tweet, press release or some other form of social media/mass media communication.

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.

(C) 2024, Halberd Corporation

A photo accompanying this announcement is available at



EN
02/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Halberd Corp.

 PRESS RELEASE

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clini...

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease JACKSON CENTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease. ...

 PRESS RELEASE

Progress Update on Halberd, Athena GTX and Athena Telemedicine Partner...

Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award! JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) partnered with Athena GTX on a profit-sharing agreement over a year ago. This enabled Halberd to utilize Athena’s expertise and experience in dealing with the federal government. Of the two technologies associated with Traumatic Brain Injuries (TBI)/Suicide Ideation for which we chose to pursue government funding, Athena’s s...

 PRESS RELEASE

Halberd Update on WatchDawg® PTSD Treatment

Halberd Update on WatchDawg® PTSD Treatment Next Phase Pilot Study JACKSON CENTER, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found . Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studi...

 PRESS RELEASE

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatme...

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System JACKSON CENTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wore a wr...

 PRESS RELEASE

Halberd Partnership Secures Contract from Defense Atomics Corporation ...

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI JACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd’s LDX techno...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch